Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam

Journal of Hepatology

Volumn 51, Issue 4, 2009, Pages 667-674

  van de Laar, Thijs J W ^a,b   Molenkamp, Richard ^b   van den Berg, Charlotte ^a,b   Schinkel, Janke ^b   Beld, Marcel G H M ^b   Prins, Maria ^a,b   Coutinho, Roel A ^a,b,c   Bruisten, Sylvia M ^a,b  

^a DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Epidemiology; HCV; Immune protection; Injecting drug use; Phylogeny; Reinfection; Superinfection

Indexed keywords

NONSTRUCTURAL PROTEIN 5B; VIRUS RNA;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MALE; MOLECULAR CLONING; NETHERLANDS; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; REINFECTION; SEROPREVALENCE; SUPERINFECTION;

ADULT; BASE SEQUENCE; COHORT STUDIES; DNA PRIMERS; FEMALE; GENETIC VARIATION; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; LONGITUDINAL STUDIES; MALE; MOLECULAR SEQUENCE DATA; NETHERLANDS; PHYLOGENY; RECURRENCE; RNA, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS; SUPERINFECTION; VIRAL NONSTRUCTURAL PROTEINS; YOUNG ADULT;

EID: 69949126882     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.05.027     Document Type: Article

References (28)

1. Roy K., Hay G., Andragetti R., Taylor A., Goldberg D., and Wiessing L. Monitoring hepatitis C virus infection among injecting drug users in the European Union: a review of the literature. Epidemiol Infect 129 (2002) 577-585
2. Amon J.J., Garfein R.S., Ahdieh-Grant L., Armstrong G.L., Ouellet L.J., Latka M.H., et al. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. Clin Infect Dis 46 (2008) 1852-1858
3. Dore G.J., MacDonald M., Law M.G., and Kaldor J.M. Epidemiology of hepatitis C virus infection in Australia. Aust Fam Physician 32 (2003) 796-798
4. Seeff L.B. Natural history of chronic hepatitis C. Hepatology 36 (2002) S35-S46
5. Jauncey M., Micallef J.M., Gilmour S., Amin J., White P.A., Rawlinson W., et al. Clearance of hepatitis C virus after newly acquired infection in injection drug users. J Infect Dis 190 (2004) 1270-1274
6. Micallef J.M., Macdonald V., Jauncey M., Amin J., Rawlinson W., van Beek I., et al. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J Viral Hepat 14 (2007) 413-418
7. Herring B.L., Page-Shafer K., Tobler L.H., and Delwart E.L. Frequent hepatitis C virus superinfection in injection drug users. J Infect Dis 190 (2004) 1396-1403
8. Prince A.M., Brotman B., Lee D.H., Pfahler W., Tricoche N., Andrus L., et al. Protection against chronic hepatitis C virus infection after rechallenge with homologous, but not heterologous, genotypes in a chimpanzee model. J Infect Dis 192 (2005) 1701-1709
9. Bassett S.E., Guerra B., Brasky K., Miskovsky E., Houghton M., Klimpel G.R., et al. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology 33 (2001) 1479-1487
10. Aitken C.K., Lewis J., Tracy S.L., Spelman T., Bowden D.S., Bharadwaj M., et al. High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology 48 (2008) 1746-1752
11. Grebely J., Conway B., Raffa J.D., Lai C., Krajden M., and Tyndall M.W. Hepatitis C virus reinfection in injection drug users. Hepatology 44 (2006) 1139-1145
12. Mehta S.H., Cox A., Hoover D.R., Wang X.H., Mao Q., Ray S., et al. Protection against persistence of hepatitis C. Lancet 359 (2002) 1478-1483
13. Van den Berg C.H., Smit C., Bakker M., Geskus R.B., Berkhout B., Jurriaans S., et al. Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur J Epidemiol 22 (2007) 183-193
14. Van den Hoek J.A., van Haastrecht H.J., Goudsmit J., de Wolf F., and Coutinho R.A. Prevalence, incidence, and risk factors of hepatitis C virus infection among drug users in Amsterdam. J Infect Dis 162 (1990) 823-826
15. Beld M., Penning M., McMorrow M., Gorgels J., van den Hoek A., and Goudsmit J. Different hepatitis C virus (HCV) RNA load profiles following seroconversion among injecting drug users without correlation with HCV genotype and serum alanine aminotransferase levels. J Clin Microbiol 36 (1998) 872-877
16. Boom R., Sol C.J., Salimans M.M., Jansen C.L., Wertheim-van Dillen P.M., and van der Noordaa J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 28 (1990) 495-503
17. Beld M., Minnaar R., Weel J., Sol C., Damen M., van der Avoort H., et al. Highly sensitive assay for detection of enterovirus in clinical specimens by reverse transcription-PCR with an armored RNA internal control. J Clin Microbiol 42 (2004) 3059-3064
18. Van de Laar T.J., Langendam M.W., Bruisten S.M., Welp E.A., Verhaest I., Van Ameijden E.J., et al. Changes in risk behavior and dynamics of hepatitis C virus infections among young drug users in Amsterdam, the Netherlands. J Med Virol 77 (2005) 509-518
19. Simmonds P., Bukh J., Combet C., Deleage G., Enomoto N., Feinstone S., et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42 (2005) 962-973
20. Tamura K., Dudley J., Nei M., and Kumar S. Mega4: molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol Biol Evol 24 (2007) 1596-1599
21. Van den Berg C.H., Smit C., van Brussel G., Coutinho R.A., and Prins M. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction 102 (2007) 1454-1462
22. Aitken C.K., McCaw R.F., Bowden D.S., Tracy S.L., Kelsall J.G., Higgs P.G., et al. Molecular epidemiology of hepatitis C virus in a social network of injection drug users. J Infect Dis 190 (2004) 1586-1595
23. Currie S.L., Ryan J.C., Tracy D., Wright T.L., George S., McQuaid R., et al. A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus. Drug Alcohol Depend 93 (2008) 148-154
24. Dore G., and Micallef J. Low incidence of HCV reinfection: exposure, testing frequency, or protective immunity. Hepatology 45 (2007) 1330
25. Danta M., Semmo N., Fabris P., Brown D., Pybus O., Sabin C., et al. Impact of HIV on host-virus interactions during early hepatitis C virus infection. J Infect Dis 197 (2008) 1558-1566
26. Kamal S. Hepatitis C: a systematic review. Am J Gastroenterol 103 (2008) 1283-1297
27. Mosley J.W., Operskalski E.A., Tobler L.H., Buskell Z.J., Andrews W.W., Phelps B., et al. The course of hepatitis C viraemia in transfusion recipients prior to availability of antiviral therapy. J Viral Hepat 15 (2008) 120-128
28. Laskus T., Wang L.F., Radkowski M., Vargas H., Nowicki M., Wilkinson J., et al. Exposure of hepatitis C virus (HCV) RNA-positive recipients to HCV RNA-positive blood donors results in rapid predominance of a single donor strain and exclusion and/or suppression of the recipient strain. J Virol 75 (2001) 2059-2066